[The efficacy of spironolacton in cardiopulmonary insufficiency (author's transl)].
In 17 patients with cardiopulmonary insufficiency the authors found a significant positive inotropic heart effect and a moderate improvement of ventilation after one injection of 400 mg Spirolacton. 2. The positive inotropic effect is experimentally confirmed in 8 dwarf pigs. 3. In 13 patients with severe cardiac and cardiopulmonary insufficiency a tendency to normalization of arterial blood gases, of actual bicarbonate and of vital capacity was found. There may be an indirect effect on the respiratory center by alteration of acid-base-status and by diuresis causing diminuation of pulmonary compliance. Spironolacton seems to be a valuable therpeutical completion in cardiac and cardiopulmonary insufficency in its intravenous quick application and its oral time application.
D000818:Animals; D001639:Bicarbonates / Q000097:blood; D001784:Blood Gas Analysis; D004341:Drug Evaluation; D006168:Guinea Pigs; D006331:Heart Diseases / Q000188:drug therapy*; D006801:Humans; D008170:Lung Compliance / Q000187:drug effects; D008171:Lung Diseases / Q000188:drug therapy*; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*; D014797:Vital Capacity / Q000187:drug effects
D001639:Bicarbonates; D013148:Spironolactone
Die Wirkung von Spironolacton bei kardiopulmonaler Insuffizienz